BioPharmSignal logoBioPharmSignal

Biotech News

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Rani Therapeutics (RANI)Rani TherapeuticsCompany update

SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Høiland as Head of Strategy.

Related news

RANIRani Therapeutics2026-08-13 20:05 EST

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

RANIRani Therapeutics2026-05-15 20:05 EST

Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

View all latest news

Rani Therapeutics

Oral Biologics Delivery Rani Therapeutics develops capsules that deliver biologic drugs through the intestinal wall, seeking to replace injections with oral administration. RaniPill Platform The RaniPill capsule protects its payload during passage through the stomach and deploys a microneedle-like mechanism in the small intestine. The...

Recent company news

RANIRani Therapeutics2026-08-13 20:05 EST

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

RANIRani Therapeutics2026-08-10 12:00 EST

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

RANIRani Therapeutics2026-08-04 12:00 EST

Rani Therapeutics Appoints Michelle Gilson to Board of Directors

RANIRani Therapeutics2026-07-20 20:05 EST

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RANIRani Therapeutics2026-07-15 12:00 EST

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

Stock data

Close
0.88 USD
Market cap
96.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States